Nanoengineered microneedle arrays for enhanced delivery of long-acting HIV medicines

纳米工程微针阵列可增强长效艾滋病毒药物的输送

• 批准号: EP/S028919/1
• 负责人: Ryan Donnelly
• 金额: $ 139.58万
• 依托单位: Queen's University Belfast
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FS028919%2F1
• 关键词: Nanoengineered; microneedle; arrays; enhanced; delivery

HIV/AIDS remains a major public health threat, with approximately 36.7 million people worldwide infected. In 2016, HIV-related diseases claimed almost 1 million lives globally, with 1.8 million people being newly infected that same year. Around 20.9 million people were accessing antiretroviral therapy in 2017, constituting ~54% of adults and ~43% of children infected with the virus. . In 2016, 42% of diagnoses happened at a late stage of infection and awareness and knowledge around HIV is dropping in the UK, emphasising the value of preventative treatments. Current methods of delivering medicines for treatment and prevention of HIV are far from optimal, necessitating multiple daily tablets or painful monthly injections.In this project we will design and test a novel type of transdermal patch that has hundreds of tiny projections on its surface. Upon painless skin application, these "microneedles" will dissolve and leave behind microscopic particles of medicine for treatment or prevention of HIV. These particles will dissolve over weeks or months to deliver therapeutic doses of the medicine. We will use state-of-the art expertise, including high power computational models to design and predict the behaviour of the medicine particles, speeding up product design and informing laboratory experiments.The technology developed here is unique and could potentially revolutionise prevention and treatment of HIV infection. It offers the opportunity for dramatically improved treatment, with potential benefits for both patients and the NHS. Ultimately, commercialisation of the technology will be the primary route by which UK industry, the NHS and patients will derive benefits. In order to attract potential industrial or venture-funding partners, it is vitally important to demonstrate proof of concept for this technology, which is the over-arching aim of the present proposal.

艾滋病毒/艾滋病仍然是一个主要的公共卫生威胁，全世界约有 3670 万人受到感染。 2016年，艾滋病毒相关疾病夺去了全球近100万人的生命，同年新增感染者180万人。 2017 年，约有 2090 万人接受了抗逆转录病毒治疗，约占感染该病毒的成人的 54%，约占感染该病毒的儿童的 43%。 。 2016 年，42% 的诊断发生在感染晚期，英国对艾滋病毒的认识和知识正在下降，凸显了预防性治疗的价值。目前治疗和预防艾滋病毒的药物输送方法远非最佳，需要每天服用多次药片或每月注射痛苦的药物。在这个项目中，我们将设计和测试一种新型透皮贴剂，其表面有数百个微小的突起。在无痛皮肤应用后，这些“微针”会溶解并留下用于治疗或预防艾滋病毒的药物微粒。这些颗粒将在数周或数月内溶解以提供治疗剂量的药物。我们将利用最先进的专业知识，包括高功率计算模型来设计和预测药物颗粒的行为，加快产品设计并为实验室实验提供信息。这里开发的技术是独一无二的，有可能彻底改变疾病的预防和治疗艾滋病毒感染。它提供了显着改善治疗的机会，对患者和 NHS 都有潜在的好处。最终，该技术的商业化将成为英国工业界、NHS 和患​​者受益的主要途径。为了吸引潜在的工业或风险投资合作伙伴，展示该技术的概念验证至关重要，这是本提案的首要目标。

项目成果

Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans

基于生理学的卡博特韦微阵列贴片在大鼠和人类体内的药代动力学模型

• DOI: http://dx.10.3390/pharmaceutics15122709
• 发表时间: 2023
• 期刊: Pharmaceutics
• 影响因子: 5.4
• 作者: Kinvig H

Ring inserts as a useful strategy to prepare tip-loaded microneedles for long-acting drug delivery with application in HIV pre-exposure prophylaxis

环插入物作为一种有用的策略来制备用于长效药物输送的尖端装载微针，并应用于 HIV 暴露前预防

• DOI: http://dx.10.1016/j.matdes.2022.111416
• 发表时间: 2022
• 期刊: Materials & Design
• 影响因子: 8.4
• 作者: Paredes A

Solid implantable devices for sustained drug delivery.

用于持续药物输送的固体植入装置。

• DOI: http://dx.10.1016/j.addr.2023.114950
• 发表时间: 2023
• 期刊: Advanced drug delivery reviews
• 影响因子: 16.1
• 作者: Magill E

The promise of microneedle technologies for drug delivery.

微针技术在药物输送方面的前景。

• DOI: 10.1007/s13346-023-01430-8
• 发表时间: 2023-10-02
• 期刊: Drug delivery and translational research
• 作者: R. Donnelly;M. Prausnitz
• 通讯作者: M. Prausnitz

Systemic delivery of tenofovir alafenamide using dissolving and implantable microneedle patches.

使用可溶性和植入式微针贴片全身递送替诺福韦艾拉酚胺。

• DOI: http://dx.10.1016/j.mtbio.2022.100217
• 发表时间: 2022
• 期刊: Materials today. Bio
• 作者: Paredes AJ